Edition:
United States

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

6.50USD
12:25pm EDT
Change (% chg)

$0.25 (+4.00%)
Prev Close
$6.25
Open
$6.25
Day's High
$6.50
Day's Low
$6.25
Volume
3,504
Avg. Vol
26,618
52-wk High
$8.35
52-wk Low
$2.45

Select another date:

Thu, May 10 2018

BRIEF-KemPharm Reports Q1 Loss Per Share $1.77

* KEMPHARM ANNOUNCES POSITIVE, TOPLINE RESULTS FROM AN INTRAVENOUS HUMAN ABUSE POTENTIAL TRIAL WITH KP415 PRODRUG; REPORTS Q1 2018 RESULTS

BRIEF-Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHD

* KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM KP415 PHARMACOKINETIC STUDY IN CHILDREN AND ADOLESCENTS WITH ADHD

KemPharm's opioid painkiller gets FDA approval, shares soar

KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading.

UPDATE 1-KemPharm's opioid painkiller gets FDA approval, shares soar

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading.

BRIEF-Kempharm Announces FDA Approval Of Apadaz

* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC

FDA approves KemPharm's opioid painkiller

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain. The company resubmitted the drug's marketing application for review in September last year after appealing against the drug regulator's decision to reject it in 2016.

Select another date: